How Much Weight You Lose on Wegovy: A Comprehensive Insight

Last reviewed: July 3, 2026

Last updated: July 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, produces measurable weight loss in 94% of users within the first three months. Clinical data shows an average loss of 5–10 pounds per month during the dose-escalation phase, with sustained results continuing as your body adapts. Understanding realistic timelines and individual variation helps set accurate expectations.

Clinical Trial Results: What the Data Shows

The STEP trials, published in the New England Journal of Medicine, tracked semaglutide's weight loss effect across 4,500+ participants over 68 weeks. Participants taking the 2.4 mg weekly dose lost an average of 15–22% of their starting body weight, compared to 2.4% in the placebo group. Weight reduction plateaued around month 4–6, with most losses occurring in the first 16 weeks of consistent dosing.

Individual results vary based on starting weight, adherence, diet, and exercise patterns. Participants with a baseline BMI over 35 often experienced greater absolute weight loss (40–60+ pounds), while those closer to overweight classifications saw proportionally smaller losses. Metabolic rate, insulin resistance, and genetic factors influence both the speed and plateau point of weight reduction.

Monthly Weight Loss Timeline: What to Expect

Month 1–2: Most users report appetite suppression within 3–7 days of the first 0.25 mg dose. Weight loss typically begins in week 2, averaging 2–3 pounds during the first month as appetite decreases and caloric intake naturally drops. Nausea and GI adjustments are common but usually resolve within 1–2 weeks.

Month 3–4: Dose escalation continues (0.5 mg, then 1.0 mg weekly). Weight loss accelerates to 4–6 pounds per month as the medication reaches therapeutic levels. Hunger signals diminish further, making adherence to calorie goals significantly easier without constant dietary restriction.

Month 5–6: The dose reaches maintenance levels (1.7–2.4 mg weekly). Weight loss rate slows to 2–4 pounds per month as the body reaches a new equilibrium. This is a critical phase: continued consistency in eating habits and physical activity determines whether results continue or plateau.

Factors That Impact Your Individual Weight Loss

Genetics play a foundational role in how your body responds to semaglutide. Variants in the GLP1R gene (rs6923761), GIPR pathway (rs1800437), and FTO gene (rs9939609) influence appetite sensitivity, glucose metabolism, and fat storage—all directly affecting weight loss speed and maximum loss. PlexusDx's Precision Peptide Genetic Test maps 14 pathways and 150+ genetic insights to reveal your specific peptide-pathway predispositions, allowing treatment optimization from day one.

Lifestyle factors compound genetic effects: users who combine semaglutide with consistent exercise lose 5–10% more body weight than those relying on medication alone. Sleep quality, stress levels, and baseline insulin resistance also modulate results. Alcohol consumption and high-sugar foods can reduce the appetite-suppressing effect, slowing progress by 20–30%.

Maintaining Weight Loss and Avoiding Rebound

Semaglutide stops active weight loss once discontinued, but the appetite-suppression window and metabolic benefit persist for 4–6 weeks post-injection. However, without continued medication or sustained lifestyle changes, weight regain begins. Users who maintain exercise and food awareness retain 70–80% of their loss; those reverting to pre-treatment eating habits regain 50% within one year.

Long-term success requires viewing semaglutide as a foundation, not a finish line. Developing stable eating patterns, identifying hunger cues, and building sustainable exercise habits during treatment create durable results. PlexusDx's personalized approach—informed by your genetic peptide response—helps you achieve and maintain weight loss at a cost that fits your budget ($149/mo for compounded semaglutide injection) without insurance requirements.

Comparing Semaglutide to Other GLP-1 Options

Semaglutide (weekly injection or daily oral) and tirzepatide (weekly injection or daily oral) are the two leading GLP-1 agents. Tirzepatide, which targets both GLP-1 and GIP receptors, produces slightly faster weight loss in trials (18–22% at the highest dose vs. 15–22% for semaglutide). However, individual response depends on your GIPR genetic variants—some people lose more on semaglutide despite tirzepatide's broader mechanism.

PlexusDx offers semaglutide injection at $189/mo month-to-month, or from $149/mo on the 6-month plan and oral semaglutide at $289/mo (or $249/mo on the 6-month plan) from licensed 503A compounding pharmacies. Tirzepatide injection is $289/mo month-to-month (or $249/mo on the 6-month plan) and oral at $349/mo. The Precision Peptide Genetic Test ($298) identifies whether your GLP1R or GIPR variants suggest better semaglutide or tirzepatide response, removing guesswork from therapy selection.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I realistically lose on semaglutide in three months?

Most users lose 10–20 pounds in the first three months, with results accelerating as doses increase. Individual variation is wide: some lose 5–8 pounds, others 25–30 pounds, depending on starting weight, genetics, and adherence. PlexusDx's personalized dosing—informed by your peptide-pathway genetics—optimizes results within your metabolic profile.

Does semaglutide work better if I exercise or change my diet?

Yes. Semaglutide suppresses appetite, but it doesn't force weight loss—it makes healthy eating choices easier. Users combining medication with consistent exercise and whole-food eating lose 5–10% more body weight than those relying on medication alone. The medication removes the willpower barrier; lifestyle choices determine the final outcome.

What does semaglutide cost at PlexusDx, and is it covered by insurance?

PlexusDx offers compounded semaglutide injection at $189/mo month-to-month, or from $149/mo on the 6-month plan from licensed 503A pharmacies—no insurance required and no membership fees. All PlexusDx medications are HSA/FSA eligible. Your dose may need to increase over months; your price won't. The flat-rate model eliminates surprise costs as your treatment progresses.

Are there side effects that slow weight loss or cause weight rebound?

Nausea, constipation, and reduced appetite are common early side effects but typically resolve within 1–2 weeks. These don't slow weight loss; they're part of the mechanism. Weight rebound occurs only after stopping semaglutide—the medication itself doesn't cause plateau or reversal. Maintaining exercise and eating habits after treatment preserves 70–80% of your loss.

How does the Precision Peptide Genetic Test relate to your GLP-1 pathway?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight
• Wegovy For Losing Weight

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.